藤野 初江HATSUE FUJINO

Last Updated :2024/05/08

所属・職名
病院（医）　助教
メールアドレス
fujino920hiroshima-u.ac.jp
自己紹介
肝炎ウイルス、肝癌に関する研究・診療を行っています。

基本情報

学歴

  • 広島大学, 医学部, 医学科, 日本, 2001年04月, 2007年03月
  • 広島大学, 大学院医歯薬保健学研究科, 博士課程医歯薬学専攻, 日本, 2013年04月, 2017年03月

学位

  • 博士（医学）　(広島大学)

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

研究キーワード

  • 肝炎ウイルス
  • 肝硬変

所属学会

  • 日本内科学会
  • 日本消化器病学会
  • 日本消化器内視鏡学会
  • 日本肝臓学会

教育活動

授業担当

  1. 2024年, 学部専門, 通年, 器官・システム病態制御学I
  2. 2024年, 学部専門, 集中, 臨床実習入門プログラム
  3. 2024年, 学部専門, 集中, 臨床実習I
  4. 2024年, 学部専門, 集中, 臨床実習II
  5. 2024年, 学部専門, セメスター（前期）, 内科学I

研究活動

学術論文（★は代表的な論文）

  1. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, CANCERS, 15巻, 8号, 202304
    DOIを用いた論文検索結果へのリンク
  2. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227巻, 5号, pp. 686-695, 20230301
    DOIを用いた論文検索結果へのリンク
  3. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions, CANCERS, 15巻, 3号, 202302
    DOIを用いた論文検索結果へのリンク
  4. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography, JOURNAL OF MEDICAL ULTRASONICS, 50巻, 1号, pp. 57-62, 202301
    DOIを用いた論文検索結果へのリンク
  5. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices, BMC GASTROENTEROLOGY, 22巻, 1号, 20221222
    DOIを用いた論文検索結果へのリンク
  6. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma, INTERNATIONAL JOURNAL OF CANCER, 151巻, 12号, pp. 2278-2290, 20221215
    DOIを用いた論文検索結果へのリンク
  7. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis, JOURNAL OF MEDICAL ULTRASONICS, 49巻, 3号, pp. 443-450, 202207
    DOIを用いた論文検索結果へのリンク
  8. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection, JOURNAL OF GASTROENTEROLOGY, 57巻, 9号, pp. 676-683, 202209
    DOIを用いた論文検索結果へのリンク
  9. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection., J Gastroenterol, 2022
  10. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis., J Med Ultrason, 2022
  11. HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL., J Infect Dis, 2022
  12. Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma., Liver Cancer, 2021
  13. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion., Clin J Gastroenterol, 7巻, 4号, pp. 333-337, 2014
  14. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment, PLOS ONE, 17巻, 1号, 20220118
    DOIを用いた論文検索結果へのリンク
  15. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84巻, 3号, pp. 391-399, 202203
    DOIを用いた論文検索結果へのリンク
  16. Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene, CASE REPORTS IN GASTROENTEROLOGY, 16巻, 1号, pp. 110-115, 2022
    DOIを用いた論文検索結果へのリンク
  17. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37巻, 3号, pp. 592-599, 202203
    DOIを用いた論文検索結果へのリンク
  18. ★, Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 607-617, 2015
    DOIを用いた論文検索結果へのリンク
  19. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48巻, 4号, pp. 264-274, 2018
    DOIを用いた論文検索結果へのリンク
  20. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp. 107-118, 2018
    DOIを用いた論文検索結果へのリンク
  21. ★, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp. 1548-1556, 2014
    DOIを用いた論文検索結果へのリンク
  22. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12巻, 8号, 2017
    DOIを用いた論文検索結果へのリンク
  23. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, Antiviral Therapy, 23巻, 3号, pp. 239-248, 2018
    DOIを用いた論文検索結果へのリンク
  24. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52巻, 3号, pp. 366-375, 2017
    DOIを用いた論文検索結果へのリンク
  25. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46巻, 12号, pp. 1256-1263, 2016
    DOIを用いた論文検索結果へのリンク
  26. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46巻, 9号, pp. 944-948, 2016
    DOIを用いた論文検索結果へのリンク
  27. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31巻, 5号, pp. 1009-1015, 2016
    DOIを用いた論文検索結果へのリンク
  28. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25巻, 11号, pp. 3272-3281, 2015
    DOIを用いた論文検索結果へのリンク
  29. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 656-662, 201506
    DOIを用いた論文検索結果へのリンク
  30. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 705-710, 201506
    DOIを用いた論文検索結果へのリンク
  31. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 4号, pp. 726-732, 201504
    DOIを用いた論文検索結果へのリンク
  32. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E420-E427, 201412
    DOIを用いた論文検索結果へのリンク
  33. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E447-E454, 201412
    DOIを用いた論文検索結果へのリンク
  34. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 44巻, 13号, pp. 1320-1328, 201412
    DOIを用いた論文検索結果へのリンク
  35. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44巻, 7号, pp. 740-749, 201407
    DOIを用いた論文検索結果へのリンク
  36. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29巻, 5号, pp. 1035-1042, 201405
    DOIを用いた論文検索結果へのリンク
  37. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61巻, 130号, pp. 323-328, 2014
  38. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28巻, 12号, pp. 1834-1841, 201312
    DOIを用いた論文検索結果へのリンク
  39. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90巻, 12号, pp. 1834-1840, 201812
    DOIを用いた論文検索結果へのリンク
  40. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25巻, 12号, pp. 1555-1564, 201812
    DOIを用いた論文検索結果へのリンク
  41. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48巻, 13号, pp. 1118-1130, 201812
    DOIを用いた論文検索結果へのリンク
  42. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91巻, 4号, pp. 650-658, 201904
    DOIを用いた論文検索結果へのリンク
  43. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54巻, 3号, pp. 291-296, 201903
    DOIを用いた論文検索結果へのリンク
  44. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3巻, 3号, pp. 348-355, 201903
    DOIを用いた論文検索結果へのリンク
  45. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
    DOIを用いた論文検索結果へのリンク
  46. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100巻, 7号, pp. 1123-1131, 201907
    DOIを用いた論文検索結果へのリンク
  47. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12巻, 4号, pp. 341-346, 201908
    DOIを用いた論文検索結果へのリンク
  48. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19巻, 1号, 20191024
    DOIを用いた論文検索結果へのリンク
  49. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55巻, 2号, pp. 217-226, 2020
    DOIを用いた論文検索結果へのリンク
  50. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124巻, 2020
    DOIを用いた論文検索結果へのリンク
  51. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 2号, pp. 267-270, 202004
    DOIを用いた論文検索結果へのリンク
  52. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
    DOIを用いた論文検索結果へのリンク
  53. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50巻, 7号, pp. 885-888, 202007
    DOIを用いた論文検索結果へのリンク
  54. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35巻, 8号, pp. 1412-1419, 202008
    DOIを用いた論文検索結果へのリンク
  55. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
  56. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92巻, 2号, pp. 210-218, 202002
  57. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk., Clin J Gastroenterol.
  58. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 5号, pp. 867-872, 202010
    DOIを用いた論文検索結果へのリンク
  59. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1222-1233, 202011
    DOIを用いた論文検索結果へのリンク
  60. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98巻, 11号, pp. 787-797, 202011
    DOIを用いた論文検索結果へのリンク
  61. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1234-1243, 202011
    DOIを用いた論文検索結果へのリンク
  62. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28巻, 2号, pp. 400-409, 2021
    DOIを用いた論文検索結果へのリンク
  63. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222巻, 12号, pp. 2061-2070, 20201215
    DOIを用いた論文検索結果へのリンク
  64. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14巻, 1号, pp. 283-287, 2021
    DOIを用いた論文検索結果へのリンク
  65. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 66巻, 4号, pp. 1268-1275, 202104
    DOIを用いた論文検索結果へのリンク
  66. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60巻, 6号, pp. 829-837, 2021
    DOIを用いた論文検索結果へのリンク
  67. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23巻, 2021
    DOIを用いた論文検索結果へのリンク
  68. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99巻, 5号, pp. 327-335, 202104
    DOIを用いた論文検索結果へのリンク
  69. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559巻, pp. 78-83, 20210625
    DOIを用いた論文検索結果へのリンク
  70. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23巻, 1号, 202101
    DOIを用いた論文検索結果へのリンク
  71. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36巻, 6号, pp. 1685-1693, 202106
    DOIを用いた論文検索結果へのリンク
  72. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40巻, 1号, 20210626
    DOIを用いた論文検索結果へのリンク
  73. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients, MEDICINE, 100巻, 26号, 20210702
    DOIを用いた論文検索結果へのリンク
  74. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib, INTERNAL MEDICINE, 60巻, 13号, pp. 2047-2053, 2021
    DOIを用いた論文検索結果へのリンク
  75. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma, ONCOLOGY, 99巻, 8号, pp. 507-517, 2021
    DOIを用いた論文検索結果へのリンク
  76. Clinical Outcomes of 2nd-and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma, ONCOLOGY, 99巻, 8号, pp. 491-498, 202107
    DOIを用いた論文検索結果へのリンク
  77. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21巻, 1号, 20210731
    DOIを用いた論文検索結果へのリンク
  78. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28巻, 9号, pp. 1304-1311, 202109
    DOIを用いた論文検索結果へのリンク
  79. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice, CANCERS, 13巻, 16号, 202108
    DOIを用いた論文検索結果へのリンク
  80. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab, MEDICINE, 100巻, 42号, 20211022
    DOIを用いた論文検索結果へのリンク
  81. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma, CANCERS, 14巻, 2号, 202201
    DOIを用いた論文検索結果へのリンク

招待講演、口頭・ポスター発表等

  1. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells, Hatsue Fujino, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, C. Nelson Hayes, Michio Imamura and Hiroshi Aikata, The Liver Meeting 2022 AASLD, 2022年11月22日, 通常, 英語, AASLD, Washington DC
  2. Entecavir投与中のB型慢性肝炎患者における血清オートタキシン濃度の変化と肝発がん予測への有用性, 第 57 回 日本肝臓学会総会, 2021年06月17日, 通常, 日本語
  3. 核酸アナログ投与後HBV制御下での発癌リスク因子の検討, 藤野初江、今村道雄、相方浩, 第44回 日本肝臓学会西部会, 2021年12月09日, 通常, 日本語
  4. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mice to HepG2/NTCP cells, 藤野初江、今村道雄、相方浩, 第 58 回 日本肝臓学会総会, 2022年06月02日, 通常, 英語, 日本肝臓学会, 横浜
  5. B型肝炎ウイルス各種遺伝子型における感染性についての検討, 藤野　初江、柘植　雅貴、津島　健、坂宮　順子、盛生　慶、大野　敦司、中原　隆志、村上　英介、山内　理海、 河岡　友和、三木　大樹、平松　憲、茶山　弘美、今村　道雄、相方　浩、茶山　一彰, 第26回　肝細胞研究会, 2019年05月23日, 通常, 日本語
  6. Serum autotaxin levels is useful to evaluate fibrosis during entecavir therapy and to predict the development of hepatocellular carcinoma in patients with chronic Hepatitis B., Hatsue Fujino, Kei Morio, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019年, 通常, 英語, Melbourne
  7. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells., Hatsue Fujino, Maiko Namba, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019年, 通常, 英語, Melbourne
  8. 核酸アナログ内服中のＢ型慢性肝炎患者における肝線維化および発癌予測マーカーとしての血清オートタキシン濃度の有効性, 藤野　初江、相方　浩、茶山　一彰, 第61回日本消化器病学会大会, 2019年, 通常, 日本語
  9. C型慢性肝炎に対するTelaprevir/PegIFN/RBV併用療法の成績, 第99回日本消化器病学会　中国支部例会, 2013年06月15日, 通常, 日本語, 岡山
  10. IFNλ4遺伝子多型とTelaprevir/PRG-IFN/RBV治療効果の関係, 第17回日本肝臓学会大会, 2013年, 通常, 日本語, 東京
  11. C型慢性肝炎に対する最新の治療法, 第66回広島医学会総会, 2013年, 通常, 日本語
  12. Telaprevir/PEG-IFN/RBV療法施行中に急性膵炎を発症したC型肝硬変の1例, 第100回日本消化器病学会中国支部例会, 2013年, 通常, 日本語, 鳥取
  13. Vp3/4門脈腫瘍栓合併進行肝細胞癌に対する肝動注化学療法における門脈腫瘍栓への放射線療法の意義, 第40回日本肝臓学会西部会, 2013年, 通常, 日本語, 岐阜
  14. Telaprebir/PegIFN/RBV併用療法（難治例）の治療成績, 第100回消化器病学会総会, 2014年, 通常, 日本語, 東京
  15. 当科の肝硬変の成因別実態　前回調査との比較, 第50回日本肝臓学会総会, 2014年, 通常, 日本語, 東京
  16. Serum Autotaxin Levels Reflect Improvement of Liver Fibrosis in Patients with Chronic Hepatitis B during Entecavir Treatment., 2018年11月13日, 通常, 英語
  17. Hepatitis B Core-Related Antigen (HBcrAg) Is a Novel Risk Marker for Hepatocellular Carcinoma during Nucleoside Analoge Treatment., AASLD The liver meeting 2018, 2018年11月13日, 通常, 英語

受賞

  1. 2019年, Travel grant award, International HBV Meeting
  2. 2016年05月18日, 日本肝臓学会研究奨励賞, 日本肝臓学会

外部資金

競争的資金等の採択状況

  1. 科学研究費助成事業(若手研究), ヒト血清由来B型肝炎ウイルスを用いた細胞感染系の樹立, 2021年, 2024年
  2. 肝炎等克服実用化研究事業　肝炎等克服緊急対策研究事業, B型肝炎患者のドラッグフリーおよびHBs抗原陰性化を目指した治療法に関する研究, 2021年04月01日, 2022年03月31日